How can we best monitor 5-FU administration to maximize benefit to risk ratio?-Reference-Cited by-同舟云学术

How can we best monitor 5-FU administration to maximize benefit to risk ratio?

Published:2018-11-23 Issue:12 Volume:14 Page:1303-1313
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Goirand Françoise¹,Lemaitre Florian²,Launay Manon³,Tron Camille²,Chatelut Etienne⁴,Boyer Jean-Christophe⁵,Bardou Marc⁶,Schmitt Antonin⁷

Affiliation:

1. Centre Hospitalo-Universitaire de Dijon-Bourgogne, Dijon, France

2. Service de Pharmacologie Clinique, Laboratoire de Pharmacologie Expérimentale et Clinique, Centre d’Investigation Clinique INSERM 1414, CHU de Rennes, Université Rennes 1, Rennes, France

3. Service de Pharmacologie, Hôpital Européen Georges Pompidou, Laboratoire de Pharmacologie et de Toxicologie, Paris, France

4. Institut Claudius-Regaud et Centre de Recherches en Cancérologie de Toulouse, IUCT - Oncopole, Toulouse, France

5. Laboratoire de Biochimie et Biologie Moléculaire, CHU de Nîmes Carémeau, Nîmes, France

6. Centre d’Investigations Cliniques 1432, Module Plurithématique, CHU Dijon-Bourgogne, Hôpital François Mitterrand, Dijon, France

7. Service Pharmacie, Centre Georges-François Leclerc, Dijon, France

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2018.1550484

Reference70 articles.

1. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil

2. Severe Toxicity Related to the 5-Fluorouracil/Leucovorin Combination (The Mayo Clinic Regimen)

3. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity

4. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis

5. Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Avenanthramide A potentiates Bim-mediated antineoplastic properties of 5-fluorouracil via targeting KDM4C/MIR17HG/GSK-3β negative feedback loop in colorectal cancer;Acta Pharmaceutica Sinica B;2024-07

2. Topical delivery of drugs in the treatment of high-grade cervical squamous intraepithelial lesions: A meta-analysis;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-05

3. Optimizing cancer patient care with a robust assay for 5-fluorouracil quantification and in-vitro stability in human blood for therapeutic drug monitoring;Practical Laboratory Medicine;2024-05

4. Genotoxicity and cytotoxicity of antineoplastic drugs at environmentally relevant concentrations after long-term exposure;Toxicology Research;2024-03-01

5. Preparation and Characterization of Novel Polyelectrolyte Liposomes Using Chitosan Succinate Layered over Chitosomes: A Potential Strategy for Colon Cancer Treatment;Biomedicines;2024-01-08